An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...
Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of ...
Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...
4d
GlobalData on MSNPfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patientsPharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...
The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its ...
Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...
The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...
Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...
Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results